UBS AM
PRAX icon

UBS AM’s Praxis Precision Medicines PRAX Stock Holding History

UBS AM’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Sell
36,187
-1,958
-5% -$620K ﹤0.01% 1143
2026
Q1 		$12.3M Buy
38,145
+2,857
+8% +$884K ﹤0.01% 1098
2025
Q4 		$10.4M Buy
35,288
+11,532
+49% +$2.15M ﹤0.01% 1110
2025
Q3 		$1.26M Sell
23,756
-73,189
-75% -$3.55M ﹤0.01% 1934
2025
Q2 		$4.08M Buy
96,945
+9,864
+11% +$376K ﹤0.01% 1806
2025
Q1 		$3.3M Buy
87,081
+68,466
+368% +$4.28M ﹤0.01% 1772
2024
Q4 		$1.43M Buy
18,615
+2,747
+17% +$199K ﹤0.01% 2201
2024
Q3 		$913K Sell
15,868
-6,014
-27% -$325K ﹤0.01% 2440
2024
Q2 		$905K Buy
+21,882
New +$1.03M ﹤0.01% 2426
2022
Q4 		– Sell
-1,747
Closed -$59.5K – 2704
2022
Q3 		$59.5K Buy
+1,747
New +$87K ﹤0.01% 2711

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

UBS AM's PRAX Position: Q2 2026 in Review

UBS AM reduced its Praxis Precision Medicines (PRAX) stake by 5.1% in Q2 2026, selling an estimated $620K and leaving 36,187 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1143.

UBS AM first reported a position in PRAX in Q3 2022 and has held it in 10 quarters since. The position peaked at $12.3M in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • UBS AM held 36,187 shares of Praxis Precision Medicines worth $12.1M as of Q2 2026.
  • UBS AM sold 1,958 Praxis Precision Medicines shares in Q2 2026, an estimated $620K.
  • Praxis Precision Medicines made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1143 holding.
  • UBS AM first reported a position in Praxis Precision Medicines in Q3 2022 and has held it in 10 quarters since.
  • UBS AM's Praxis Precision Medicines position peaked at $12.3M in Q1 2026.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.